你即將離開本站

並前往https://www.evaluate.com/vantage/articles/analysis/read-my-lips-no-humira-biosimilars-until-2022

Read my lips: no Humira biosimilars until 2022 | Evaluate

This is vastly at odds with sellside expectations, as shown by EvaluatePharma consensus data, and prompted a 10% jump in AbbVie stock – though ...

確定！ 回上一頁

查詢 「Humira stock」的人也找了：

  1. AbbVie
    2.
  2. Amgen stock
    3.
  3. Adm stock
    4.
  4. abbvie產品
    5.
  5. MO stock
    6.
  6. BMY stock
    7.
  7. Novartis stock
    8.
  8. J.P. stock
    9.